Johannes Ungermann

Mr. Johannes Ungermann

University of Heidelberg, Germany
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MFMargaux Fresnais
Margaux Fresnais
Sevin TurcanSevin Turcan
Sevin Turcan
DTDirk Theile
Dirk Theile
JUJohannes Ungermann
Johannes Ungermann
YZYasmin Abou Zeed
Yasmin Abou Zeed
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
Temozolomide (TMZ), together with bulk resection and focal radiotherapy, is currently a standard of care for glioblastoma. Absorption, distribution, metabolism, and excretion (ADME) parameters, together with the mode of action of TMZ, make its biochemical and biological action difficult to understand. Accurate understanding of the mode of action of TMZ and the monitoring of TMZ at its anatomical, cellular, and molecular sites of action (SOAs) would greatly benefit precision medicine and the development of novel therapeutic approaches in combination with TMZ. In the present perspective article, we summarize the known ADME parameters and modes of action of TMZ, and we review the possible methodological options to monitor TMZ at its SOAs. We focus our descriptions of methodologies on mass spectrometry-based approaches, and all related considerations are taken into account regarding the avoidance of artifacts in mass spectrometric analysis during sampling, sample preparation, and the evaluation of results. Finally, we provide an overview of potential applications for precision medicine and drug development.

21 January 2022 in Molecules
Verified
Journal Article
Open access
PDF file
MFMargaux Fresnais
Margaux Fresnais
SKSeda Karabulut
Seda Karabulut
YZYasmin Abou Zeed
Yasmin Abou Zeed
JUJohannes Ungermann
Johannes Ungermann
JBJulia Benzel
Julia Benzel
Rémi LonguespéeRémi Longuespée
Rémi Longuespée
Desorption/ionization mass spectrometry (DI-MS) approaches allow for the rapid quantification of drugs in biological matrices using assays that can be validated according to regulatory guidelines. However, specific adaptations must be applied to create reliable quantification methods, depending on the approach and instrumentation used. In the present article, we demonstrate the importance of the molecular weight, the fragmentation pattern, and the purity of the internal standard for the development of matrix-assisted laser desorption/ionization (MALDI)-ion mobility (IM)-tandem MS and MS/MS methods. We present preliminary results of method development for the quantification of selinexor in microdialysis fluids with a stable isotopically labeled internal standard. In addition, we discuss the selection of internal standards for MALDI-MS assays using different instrumentations.